Blueprint Medicines Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Strong earthquake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Blueprint Medicines (BPMC) PT Raised to $52 at Jefferies
May 4, 2017 8:24 AM EDTJefferies raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $52.00 (from $42.00) while maintaining a Buy rating.
"With add'l clinical data for 2 lead candidates (BLU-285, BLU-554) in 2017 likely to strengthen their therapeutic potential, and added clarity around approval path for... More
Blueprint Medicines (BPMC) Misses Q1 EPS by 8c
May 3, 2017 7:06 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More